Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.45 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
| ▸ | NPY4R | P50391 | 7/20 | 0.39 |
| ▸ | NPY1R | P25929 | 5/20 | 0.39 |
| ▸ | NPY2R | P49146 | 4/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.39 |
| ▸ | RRM1 | P23921 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | OTC | P00480 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9194730 | 1.00 | DPP7 (0.45) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL18819440 | 1.00 | DPP7 (0.45) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| Hydrochloric Acid SCHEMBL28913679 | 0.98 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| Hydrochloric Acid SCHEMBL28913681 | 0.98 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| Hydrochloric Acid SCHEMBL29065758 | 0.98 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| Hydrochloric Acid SCHEMBL29065757 | 0.98 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL18868717 | 0.89 | DPP7 (0.36) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL13660193 | 0.87 | DPP7 (0.50) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL2186467 | 0.84 | DPP7 (0.39) | DPP7GNAI3GNAO1GNAI1NPY4R | |
| SCHEMBL19465128 | 0.84 | DPP7 (0.39) | DPP7GNAI3GNAO1GNAI1NPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115466219-B | Preparation method of 1- [3- (2-amino-4-ethyl-1H-imidazol-5-yl) propyl ] guanidine | 中国科学院天津工业生物技术研究所 | 2023-09-08 | — | — | CN | claimed |
| CN-115466219-A | Preparation method of 1- [3- (2-amino-4-ethyl-1H-imidazole-5-yl) propyl ] guanidine | 中国科学院天津工业生物技术研究所 | 2022-12-13 | — | — | CN | claimed |
| CN-115466219-B | Preparation method of 1- [3- (2-amino-4-ethyl-1H-imidazol-5-yl) propyl ] guanidine | 中国科学院天津工业生物技术研究所 | 2023-09-08 | — | — | CN | disclosed |
| CN-115466219-A | Preparation method of 1- [3- (2-amino-4-ethyl-1H-imidazole-5-yl) propyl ] guanidine | 中国科学院天津工业生物技术研究所 | 2022-12-13 | — | — | CN | disclosed |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2021-11-09 | — | — | US | disclosed |
| US-11078164-B1 | PTEN binding compounds, formulations, and uses thereof | UNIVERSITY OF SOUTH FLORIDA (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200061208-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20190161450-A1 | PTEN BINDING COMPOUNDS, FORMULATIONS, AND USES THEREOF | UNIVERSITY OF SOUTH FLORIDA (US) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061208-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | DPP7 1287/4885GNAI3 2728/4885GNAO1 2326/4885 |
| US-11078164-B1 | PTEN binding compounds, formulations, and uses thereof | PTEN, EYA2, PIK3CA | DPP7 3328/4885GNAI3 409/4885GNAO1 867/4885 |
| US-20190161450-A1 | PTEN BINDING COMPOUNDS, FORMULATIONS, AND USES THEREOF | PTEN, EYA2, PIK3CA | DPP7 3328/4885GNAI3 409/4885GNAO1 867/4885 |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | DPP7 1287/4885GNAI3 2728/4885GNAO1 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.